Today, UBS Asset Management Americas Inc. decreases its position in Zimmer Biomet Holdings Inc. (ZBH)

Today, UBS Asset Management Americas Inc. decreases its position in Zimmer Biomet Holdings Inc. (ZBH)
UBS Asset Management Americas Inc. decreased its stake in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 16.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,580,607 shares of the company’s stock after selling 308,184 shares during the period. UBS Asset Management Americas Inc. owned about 0.79% of Zimmer Biomet Holdings worth $205,512,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Daiwa Securities Group Inc. raised its stake in shares of Zimmer Biomet Holdings by 3.2% in the third quarter. Daiwa Securities Group Inc. now owns 4,900 shares of the company’s stock valued at $637,000 after buying an additional 150 shares in the last quarter. TIAA CREF Trust Co. FSB MO raised its stake in shares of Zimmer Biomet Holdings by 1.7% in the third quarter. TIAA CREF Trust Co. FSB MO now owns 69,724 shares of the company’s stock valued at $9,066,000 after buying an additional 1,153 shares in the last quarter. Delta Lloyd NV raised its stake in shares of Zimmer Biomet Holdings by 25.2% in the third quarter. Delta Lloyd NV now owns 14,642 shares of the company’s stock valued at $1,904,000 after buying an additional 2,947 shares in the last quarter. Pillar Pacific Capital Management LLC raised its stake in shares of Zimmer Biomet Holdings by 0.6% in the third quarter. Pillar Pacific Capital Management LLC now owns 47,815 shares of the company’s stock valued at $6,217,000 after buying an additional 300 shares in the last quarter. Finally, Retirement Systems of Alabama raised its stake in shares of Zimmer Biomet Holdings by 1.5% in the third quarter. Retirement Systems of Alabama now owns 101,160 shares of the company’s stock valued at $13,153,000 after buying an additional 1,524 shares in the last quarter. Institutional investors and hedge funds own 88.87% of the company’s stock.

Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 1.73% during mid-day trading on Friday, reaching $102.75. The company’s stock had a trading volume of 407,310 shares. Zimmer Biomet Holdings Inc. has a 52-week low of $88.27 and a 52-week high of $133.21. The firm has a market cap of $20.58 billion, a price-to-earnings ratio of 57.53 and a beta of 1.28. The firm has a 50 day moving average price of $114.43 and a 200 day moving average price of $121.78.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Monday, October 31st. The company reported $1.79 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $1.79. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The company earned $1.83 billion during the quarter, compared to analysts’ expectations of $950.20 million. During the same period last year, the firm posted $1.64 earnings per share. The business’s revenue was up 4.0% on a year-over-year basis. On average, equities analysts predict that Zimmer Biomet Holdings Inc. will post $7.92 EPS for the current fiscal year.

Several equities research analysts have recently issued reports on the company. Northcoast Research lowered Zimmer Biomet Holdings from a “buy” rating to a “neutral” rating in a report on Tuesday, November 8th. Leerink Swann reiterated an “outperform” rating and set a $136.00 price target (down from $150.00) on shares of Zimmer Biomet Holdings in a report on Tuesday, November 1st. RBC Capital Markets restated an “outperform” rating and issued a $130.00 target price (down from $143.00) on shares of Zimmer Biomet Holdings in a report on Tuesday, November 1st. Royal Bank Of Canada reduced their target price on Zimmer Biomet Holdings from $143.00 to $130.00 and set an “outperform” rating for the company in a report on Tuesday, November 1st. Finally, Needham & Company LLC upgraded Zimmer Biomet Holdings from a “buy” rating to a “strong-buy” rating and reduced their target price for the stock from $150.00 to $148.00 in a report on Tuesday, November 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $131.15.

In other news, insider Daniel E. Williamson sold 2,716 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $129.96, for a total value of $352,971.36. Following the completion of the sale, the insider now directly owns 2,000 shares of the company’s stock, valued at $259,920. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.22% of the stock is owned by insiders.

Zimmer Biomet Holdings Company Profile

Related posts

Leave a Comment